Compare Las Vegas Sands Corp. (LVS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Twist Bioscience Corp — how do they compare? Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Las Vegas Sands Corp. is far larger — about 2.3× Twist Bioscience Corp's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Twist Bioscience Corp for 27 Days on average.
| LVS | TWST | |
|---|---|---|
Market Cap | $23.38B | $10.08B |
Volume | 6,994,661 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $205.00 |
52-Week Low | $35.81 | $25.45 |
Typical Hold Time | 72 Days | 27 Days |
Enterprise Value | $35.27B | $10.01B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.10, up 0.81% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with $13.02B revenue, 12.59% net margin, and positive cash flow of $191M in 2025. Recent news highlights Sands China's community initiatives and operational milestones, while analyst consensus remains strongly bullish with a $59.78 price target.
LVS presents a compelling value opportunity with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). However, high debt levels and recent Q2 2026 earnings miss pose risks. The significant upside to analyst targets suggests potential for substantial returns if operational execution improves.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
